Feed

Peritoneal surface malignancies represent a metastatic pattern of advanced gastrointestinal and other malignant tumors, which are difficult to treat and associated with poor prognosis. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) is the standard treatment for peritoneal tumors recommended by the Peritoneal Surface Oncology Group International (PSOGI). In recent years, peritoneal tumors have evolved from a "cold" field to a "hot" topic in oncological academia. An increasing number of prospective clinical studies have been published worldwide, providing new insights into the management of peritoneal tumors. At the 2025 PSOGI Congress, several issues emerged as key research hotspots in peritoneal tumors, including the presentation of the CAIRO6 trial on preoperative chemotherapy for CRS, the pros and cons debate on the application value of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in peritoneal tumors, the impact of pathological types on survival prognosis, the value of laparoscopic minimally invasive techniques in CRS, and the selection of chemotherapeutic agents for HIPEC. China has kept pace with international developments in the field of peritoneal tumors, conducting a series of studies ranging from clinical research to basic translational research. This article reviews the similarities and differences in the treatment of peritoneal tumors between China and abroad, as well as the pathological diagnosis and classification, patient selection for CRS, key points in the implementation of CRS and HIPEC, differences in preoperative chemotherapy regimens, and selection of HIPEC chemotherapeutic agents, aiming to provide new ideas for the therapeutic direction of peritoneal tumors.